#168
|
|||
|
|||
Ïîñòàíîâêà êàòåòåðà â ðåòðîáóëüáàðíîå ïðîñòðàíñòâî äëÿ äîñòàâêè ýìîêñèïèíà è ïðî÷èõ ôóôëîìèöèíîâ â ëå÷åíèè ïàòîëîãèè ãëàç ó äåòåé - æåñòîêî, áåññìûñëåííî, îïàñíî, ò.ê. ïðîöåäóðà âûïîëíÿåòñÿ ïîä íàðêîçîì.
|
#169
|
||||
|
||||
Íå ïîäñêàæåòå äèññåð, îòêóäà ýòî ïîøëî? Èëè ýòî òîëüêî â îäíîì ó÷ðåæäåíèè ïðèìåíÿåòñÿ?
p.s. íàø¸ë [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ìîæíî íà àâòîðà ïîñìîòðåòü. |
#170
|
||||
|
||||
First experience of usage of combined method
of treatment of dystrophic diseases of retina and optic nerve V.I. Baranov, A.I. Bereznikov, O.A. Danilenko, T.A. Myasnikova, A.Yu. Brezhnev Kursk State Medical University Department of Ophthalmology Purpose: to analyze effect of combined treatment including catheterization of retrobulbar space, electromagnetic stimulation, pharmacotherapy and implantation of collagen sponge sodden by drug solution in Tenon’s space. Materials and methods: 36 patients with dystrophic diseases of retina and optic nerve were included into the study. Visometry, perimetry, flicker fusion frequency test were performed at the beginning and at the end of treatment course. In some cases x–rate and ultrasound examination were carried out if needed. Control group consisted of 6 patients with POAG of developed and severe stages and 5 patients with partial optic nerve atrophy. Patients of studied groups were treated with collagen sponge implantation sodden with retinalamin or emoxipin solution. In control group patients received standard treatment with emoxipin, mildronat, taufon and piracetam. Results: Combined treatment with collagen sponge usage turned out to be more effective method of treatment of retinal and optic nerve dystrophic diseases then classic pharmacotherapy combined with electromagnetic stimulation. Àòàñ... Îñîáåííî êîíòðîëü õîðîøèé. Ìåòîäèêà äîëæíà ïðîéòè íà çàïàä. Çàäàâèì èõ îôòàëüìîëîãèþ òàíêàìè. À âîò äèññåð 2011 ã. "Õèðóðãè÷åñêèì ïóòåì â ðåòðîáóëüáàðíîå èëè òåíîíîâîå ïðîñòðàíñòâî óñòàíàâëèâàåòñÿ èððèãàöèîííàÿ ñèñòåìà, êîòîðàÿ ïîçâîëÿåò â ïîñëåäóþùåì â òå÷åíèè 10-15 äíåé áåçáîëåçíåííî ïîäâîäèòü ëåêàðñòâî ê çðèòåëüíîìó íåðâó 6-8 ðàç â äåíü. Äðîáíîå ââåäåíèå ëåêàðñòâà, ïîâûøàåò êîíöåíòðàöèþ ëåêàðñòâà è îáåñïå÷èâàåò äëèòåëüíîå åãî ïðåáûâàíèå â ãëàçó, ïîâûøàåò â 6 ðàç ýôôåêòèâíîñòü ëå÷åíèÿ. Äàííàÿ ìåòîäèêà ÿâëÿåòñÿ íà ñåãîäíÿøíåé äåíü ëó÷øåé îíà âíåäðåíà è øèðîêî ïðèìåíÿåòñÿ âî ìíîãèõ êëèíèêàõ ñòðàíû. Ýòîò êóðñ òåðàïèè ïîâûøàåò áèîýíåðãåòè÷åñêèé óðîâåíü è óëó÷øàåò ìèêðîöèðêóëÿöèþ íåðâíîé òêàíè. Íà ôîíå ýòîãî êóðñà íà÷èíàþò ïðîâîäèòü ñòèìóëÿöèþ çðèòåëüíîãî íåðâà (Ëîáàíîâà È.Â., 1997)." Ïîõîäó ïîêà ïðåìèé çà ëå÷åíèå ÷àçí íå ïîëó÷èëè. À æàëü. |
#172
|
|||
|
|||
 Êóðñêå ýòî íà ïîòîêå. Êîãäà ó÷èëñÿ - ïîñòîÿííî âèäåë ïàöèåíòîâ ñ òðóáêàìè èç ãëàç, áðîäÿùèõ ïî òåððèòîðèè. Äåòåé, ïðàâäà, íå âñòðå÷àë...
|
#173
|
||||
|
||||
Ðàíäîìèçèðîâàííûõ ñëåïûõ êîíòðîëèðóåìûõ èññëåäîâàíèé òàêîãî âèäà ëå÷åíèÿ â Êóðñêå íå ïðîâîäèëè?
|
#174
|
|||
|
|||
Àãà, ïðîâîäèëè. Çàâÿçûâàëè âñåì ãëàçà - è ïðîâîäèëè. Ñìå¸òåñü, ÷òî ëè?  Ðîññèè âîîáùå ïðîâîäÿò òàêèå?
|
#175
|
||||
|
||||
Ïðîâîäÿò ñëåïî ñðàâíèâàÿ äâà ñë¸çíûõ ïðåïàðàòà - ñäèðàþò ñ îðèãèíàëüíûõ áóòûëîê ýòèêåòêó, è âîò óæå íèêòî íå çíàåò, ãäå õèëîêîìîä, à ãäå ñèñòåéí.
|
#176
|
|||
|
|||
Ïî÷èòàëà èíôó ïî âòîðîé ññûëêå â ïîèñêå. Ëå÷àò êîñîãëàçèå. Ìîíîëàòåðàëüíîå, ïóñòü è ñ ×ÀÇÍ. Î ñîñòîÿíèè çðèòåëüíîé ôèêñàöèè íè ñëîâà.
Âñå, ïðèïëûëè, äàëüøå ìîæíî íå ÷èòàòü. È ýòî ÐÃÌÓ, ó÷åíèêè Ñèäîðåíêî, àâòîðà ó÷åáíèêà ïî äåòñêîé îôòàëüìîëîãèè. "Ëå÷åíèþ" ïîäâåðãàëè äåòåé îò 3 äî 13 ëåò. Áûëà ãðóïïà êîíòðîëÿ, èì äâàæäû äàâàëè íàðêîç, â ïåðâûé äëÿ îïåðàöèè ïî óñòðàíåíèþ êîñîãëàçèÿ, âòîðîé - äëÿ ïîñòàíîâêè êàòåòåðà. Êîëëåãè, âû ìíîãî âèäåëè äåòåé ñ ìîíîëàòåðàëüíûì êîñîãëàçèåì ñ öåíòðàëüíîé ôèêñàöèåé? ß íåäàâíî ðàáîòàþ, ó ìåíÿ èõ åäèíèöû. |
#177
|
||||
|
||||
Ïî÷èòàéòå ïðî àìáëèîïèþ ïîñëåäíþþ ñòàòüþ Õîéòà (Hoyt), òîãî, ÷òî àâòîð àìåð.ó÷åáíèêà ïî äåòñòêîé îôò è êîñîãëàçèþ. Îí òîæå ñïèñûâàåò ïëåîïòèêó â óòèëü, ïðè ÷¸ì íå ñåé÷àñ, åù¸ ãîäàõ â øåñòèäåñÿòûõ.. Ìû íå îäíè òàêèå.
|
#178
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Óâû, ëåâîäîïà äëÿ àìáëèîïèè ïîïàëà â ýòîò æå ñïèñîê. Ïðàâäà â òîì æå ñïèñêå - ïëåîïòèêà. |
#179
|
||||
|
||||
ß áû õîòåë ïîÿñíèòü.
Ïëåîïòèêà ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] â íàö. ðóêîâîäñòâå) åñòü ñèñòåìà ìåòîäîâ, íàïðàâëåííàÿ íà ëå÷åíèå àìáëèîïèè. Íå îíà ñàìà (ñèñòåìà ìåòîäîâ) â òîì æå ñïèñêå, à áîëüøèíñòâî ìåòîäîâ èç òîãî ñïèñêà, ÷òî ïëåîïòèêà â ñåáÿ âêëþ÷àåò, çà èñêëþ÷åíèåì íåêîòîðûõ íàèáîëåå ýôôåêòèâíûõ: 1. Îêêëþçèÿ. 2. Îïòè÷åñêàÿ ïåíàëèçàöèÿ. 3. Ôàðìàêîëîãè÷åñêàÿ ïåíàëèçàöèÿ. 4. Êîððåêöèÿ àíîìàëèé ðåôðàêöèè. Îñòàëüíûå ìåòîäû, òàêèå êàê, àïïàðàòíûå ñòèìóëÿòîðû, ëåâîäîïà, ðåôëåêñîòåðàïèÿ, çàñâåòû ðàçëè÷íûõ ìîäèôèêàöèé, äèõîïòè÷åñêèå âèäåîòðåíàæ¸ðû, ïîäêîæíîå ââåäåíèå ôàðì.ïðåïàðàòîâ íå èìåþò íà ñåé äåíü äîêàçàòåëüñòâ ýôôåêòèâíîñòè â õîðîøî ñïëàíèðîâàííûõ êîíòðîëèðóåìûõ èññëåäîâàíèÿõ. À íåêîòîðûå èç ïåðå÷èñëåííûõ ìåòîäîâ, òà æå ëåâîäîïà, ÷òî ìîæíî ïðî÷åñòü â ïðèâåä¸ííîé âûøå ñòàòüå, â ðàíäîìèçèðîâàííîì ìóëüòèöåíòðîâîì ïëàöåáî-êîíòðîëèðóåìîì èññëåäîâàíèè ñ îáùèì êîëè÷åñòâîì äåòåé ñ àìáëèîïèåé = 139, ïðîâåä¸ííîì the Pediatric Eye Disease Investigator Group, ïîêàçàëè ñâîþ ïîëíóþ íåýôôåêòèâíîñòü, ïîýòîìó îò èõ ïðèìåíåíèÿ â êëèíè÷åñêîé ïðàêòèêå ïðèçâàíî îòêàçàòüñÿ. |
#180
|
||||
|
||||
|